Identification and characterization of nodal metastases in prostate cancer patients at high risk for lymph node involvement

References

• Gervasi LA, Mata J, Easley JD, Wilbanks JH, Seale-Hawkins C, Carlton CE Jr, et al. Prognostic significance of lymph nodal metastases in prostate cancer. J Urol 1989;142: 332–6.
   PubMed Web of Science ®Google Scholar
• Joniau S, Van den Bergh L, Peeters C, Haustermans K, Spahn M. Nodal staging in prostate cancer: Still an unresolved issue. Eur Urol 2012;61:1139–41.
   PubMed Web of Science ®Google Scholar
• Malmstrom PU. Lymph node staging in prostatic carcinoma revisited. Acta Oncol 2005;44:593–8.
   PubMed Web of Science ®Google Scholar
• Shariat SF, Semjonow A, Lilja H, Savage C, Vickers AJ, Bjartell A. Tumor markers in prostate cancer I: Blood-based markers. Acta Oncol 2011;50(Suppl 1):61–75.
   PubMed Web of Science ®Google Scholar
• Duff SE, Li C, Garland JM, Kumar S. CD105 is important for angiogenesis: Evidence and potential applications. FASEB J 2003;17:984–92.
   PubMed Web of Science ®Google Scholar
• Padua D, Massague J. Roles of TGFbeta in metastasis. Cell Res 2009;19:89–102.
   PubMed Web of Science ®Google Scholar
• Shevde LA, Das S, Clark DW, Samant RS. Osteopontin: An effector and an effect of tumor metastasis. Curr Mol Med 2010;10:71–81.
   PubMed Web of Science ®Google Scholar
• Saharinen P, Eklund L, Pulkki K, Bono P, Alitalo K. VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol Med 2011;17:347–62.
   PubMed Web of Science ®Google Scholar
• Chen Q, Massague J. Molecular pathways: VCAM-1 as a potential therapeutic target in metastasis. Clin Cancer Res 2012;18:5520–5.
   PubMed Web of Science ®Google Scholar
• Shariat SF, Karam JA, Walz J, Roehrborn CG, Montorsi F, Margulis V, et al. Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers. Clin Cancer Res 2008;14:3785–91.
   PubMed Web of Science ®Google Scholar
• Shariat SF, Anwuri VA, Lamb DJ, Shah NV, Wheeler TM, Slawin KM. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. J Clin Oncol 2004;22:1655–63.
   PubMed Web of Science ®Google Scholar
• Briganti A, Karnes JR, Da Pozzo LF, Cozzarini C, Gallina A, Suardi N, et al. Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol 2009;55: 261–70.
   PubMed Web of Science ®Google Scholar
• Mina LA, Sledge GW, Jr. Rethinking the metastatic cascade as a therapeutic target. Nat Rev Clin Oncol 2011;8: 325–32.
   PubMed Web of Science ®Google Scholar
• Sabbah M, Emami S, Redeuilh G, Julien S, Prevost G, Zimber A, et al. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. Drug Resist Update 2008;11:123–51.
   PubMed Web of Science ®Google Scholar
• Giroldi LA, Schalken JA. Decreased expression of the intercellular adhesion molecule E-cadherin in prostate cancer: Biological significance and clinical implications. Cancer Metastasis Rev 1993;12:29–37.
   PubMed Web of Science ®Google Scholar
• Kuefer R, Hofer MD, Zorn CS, Engel O, Volkmer BG, Juarez-Brito MA, et al. Assessment of a fragment of e-cadherin as a serum biomarker with predictive value for prostate cancer. Br J Cancer 2005;92:2018–23.
   PubMed Web of Science ®Google Scholar
• Budiharto T, Joniau S, Lerut E, Van den Bergh L, Mottaghy F, Deroose CM, et al. Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases. Eur Urol 2011;60:125–30.
   PubMed Web of Science ®Google Scholar
• Samaratunga H, Montironi R, True L, Epstein JI, Griffiths DF, Humphrey PA, et al. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 1: Specimen handling. Mod Pathol 2011;24:6–15.
   PubMed Web of Science ®Google Scholar
• Shariat SF, Shalev M, Menesses-Diaz A, Kim IY, Kattan MW, Wheeler TM, et al. Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol 2001;19:2856–64.
   PubMed Web of Science ®Google Scholar
• Svatek RS, Karam JA, Roehrborn CG, Karakiewicz PI, Slawin KM, Shariat SF. Preoperative plasma endoglin levels predict biochemical progression after radical prostatectomy. Clin Cancer Res 2008;14:3362–6.
   PubMed Web of Science ®Google Scholar
• Roobol MJ, Haese A, Bjartell A. Tumour markers in prostate cancer III: Biomarkers in urine. Acta Oncol 2011; 50(Suppl 1):85–9.
   PubMed Web of Science ®Google Scholar
• Rubin MA, Mucci NR, Figurski J, Fecko A, Pienta KJ, Day ML. E-cadherin expression in prostate cancer: A broad survey using high-density tissue microarray technology. Hum Pathol 2001;32:690–7.
   PubMed Web of Science ®Google Scholar
• Cheng L, Nagabhushan M, Pretlow TP, Amini SB, Pretlow TG. Expression of E-cadherin in primary and metastatic prostate cancer. Am J Pathol 1996;148: 1375–80.
   PubMed Web of Science ®Google Scholar
• Umbas R, Schalken JA, Aalders TW, Carter BS, Karthaus HF, Schaafsma HE, et al. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res 1992; 52:5104–9.
   PubMed Web of Science ®Google Scholar
• De Marzo AM, Knudsen B, Chan-Tack K, Epstein JI. E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens. Urology 1999;53:707–13.
   PubMed Web of Science ®Google Scholar
• Wells A, Yates C, Shepard CR. E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas. Clin Exp Metastasis 2008;25:621–8.
   PubMed Web of Science ®Google Scholar